hlx43
Non-Small Cell Squamous Lung Carcinoma
Explore 53 assets in Non-Small Cell Squamous Lung Carcinoma →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Shanghai Henlius Biotech
Modality
antibody_drug_conjugate
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07459751CT.gov A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Squamous Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| hlx43 (this asset) | Shanghai Henlius Biotech | P2/3 | B · 57 |
| Carboplatin | Gruppo Oncologico Italiano di Ricerca Clinica | P3 | BBB |
| Pembrolizumab | Shanghai Henlius Biotech | P3 | BB |
| Serplulimab | Shanghai Henlius Biotech | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Gruppo Oncologico Italiano di Ricerca Clinica | P3 | BB |
| Docetaxel | Shanghai Henlius Biotech | P3 | BB |
| Tislelizumab | BeOne Medicines | P3 | BB |
| Catequentinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P3 | BB |
| Olaparib | Merck Sharp & Dohme LLC | P3 | BB |
+42 more in the Non-Small Cell Squamous Lung Carcinoma cohort
Other indications for hlx43
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Tumor Luminal A Or B | — | P2 | CCC · 53 |
| Triple-Negative Breast Carcinoma | — | P2 | CCC · 53 |
| Hepatocellular Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. hlx43 in Non-Small Cell Squamous Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hlx43-non-small-cell-squamous-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →